<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Dave Invest-wards - Medium]]></title>
        <description><![CDATA[Welcome to my collection of articles around investing, where I will post a little about my investing philosophy, what I’m looking at, and what’s new in my portfolio - Medium]]></description>
        <link>https://medium.com/dave-invest-wards?source=rss----cdf37c015905---4</link>
        <image>
            <url>https://cdn-images-1.medium.com/proxy/1*TGH72Nnw24QL3iV9IOm4VA.png</url>
            <title>Dave Invest-wards - Medium</title>
            <link>https://medium.com/dave-invest-wards?source=rss----cdf37c015905---4</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Tue, 17 Nov 2026 00:31:29 GMT</lastBuildDate>
        <atom:link href="https://medium.com/feed/dave-invest-wards" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Portfolio News: Tuesday 30th September]]></title>
            <link>https://medium.com/dave-invest-wards/portfolio-news-tuesday-30th-september-db0960a0b314?source=rss----cdf37c015905---4</link>
            <guid isPermaLink="false">https://medium.com/p/db0960a0b314</guid>
            <category><![CDATA[stocks]]></category>
            <category><![CDATA[value-investing]]></category>
            <category><![CDATA[investing]]></category>
            <dc:creator><![CDATA[David Edwards]]></dc:creator>
            <pubDate>Wed, 01 Oct 2025 11:45:17 GMT</pubDate>
            <atom:updated>2025-10-01T11:45:00.667Z</atom:updated>
            <content:encoded><![CDATA[<p><strong>What’s new</strong></p><p>Whilst most of my portfolio focuses on value stocks, I have a small number set aside as “wildcards.” These are the kinds of businesses that Benjamin Graham wouldn’t think twice about, and which “The Intelligent Investor” recommends running away from at full speed. I, however, was curious to see whether taking a few of these might cause some interesting effects on the portfolio.</p><p>I have a couple of different categories, but while I was browsing across different categories, I came across a potential “Growth” stock which caught my attention. It was in the “Health” industry, which I don’t like to begin with because the finance model leads to a lot of small or speculative businesses on the market. This one, however, seemed to have extremely positive analyst sentiment, from its 100% buy recommendation to its insanely high price target. Its name was ATAI life sciences, so I took a look.</p><p>As I looked more closely, there were things which I was extremely concerned about. It had -0.7 earnings per share, and a -5,000% profit margin. What was the fuss about? Looking at what it was working on, it started to make sense — ATAI is pursuing research on psilocybin treatments for depression. We’d watched a documentary a few years ago about hallucinogenic drugs and magic mushrooms and their potential for the treatment of depression, so I was interested, but it seemed that the political environment may be turning in the favour of ATAI — Trump had won the election (but not started office yet), and it was clear that Robert Kennedy, his radical pick for Health Secretary, might be open to these alternative treatments. I took a single unit of ATAI, and if I lost it all, it wouldn’t have been the end of the world, but there was a chance that this speculative pick might develop.</p><p>Fast forward slightly: last week the company reported positive results in its most recent round of testing, and the stock price jumped from $4.60-ish to a peak of $5.84. From my buy price of $1.38, it is up 284%. I’m not a fan of speculative picks, and I’m not saying that anything other than pure luck led me to this stock. Even after I took it, I fully expected it to lose its entire value (to be honest, I still am), but I think it’s a fun experiment to diverge from your usual framework and at least take a look at these wildcard stocks, because occasionally they do behave like this.</p><p>It has since fallen back to 5.29, but I took another unit, just to see what happens…</p><p><strong>What I’ve been looking at</strong></p><p>This week I looked at European Real Estate stocks. Some of these I had seen before, but there were some new Swiss, Finnish, Danish and Austrian stocks, plus a ton of new French and German businesses to look at.</p><p>To begin with, I’m always interested in what the numbers tell about a given industry. In this case, the average Price to Book was 0.873, indicating that there is a fairly strong link between the physical assets of the company and its stock market value. In fact there were only 3 failed tests for Price to Book ratio from the sample I looked at.</p><p>The big problem with this industry was presumably the impact that Covid had. Less than half avoided negative earnings, across the past 5 years, and only 7 of the 48 companies showed EPS growth across both the 3 year and 10 year horizon. In addition, there were a lot of companies which Benjamin Graham would regard as being too small ie they had annual revenue under €500 million.</p><p>To sum up: There definitely weren’t any 6-star stocks, but there were 4 5-stars:</p><p>Merlin (Spain — slightly too small, its annual revenue was €465 million, so just under the tolerance. In my opinion, this is no big deal)</p><p>Unibail-Rodamco-Westfield (France — carrying slightly too much debt to assets, at 67.88%, but again this is not a blowout compared to the 50% reference value)</p><p>Aroundtown (Germany — had a 10 year EPS growth of -10.35% which knocked out its stability)</p><p>Aedas Homes (Spain — Lightyear didn’t display a 10 year EPS growth figure for this stock, and where data isn’t available, I regard this as a fail)</p><p>For the top 3 of these stocks, Lightyear had some analyst data, and Merlin seems very positive: 80% recommended buying the stock, and the price is projected to rise 12% to 14.36. Westfield had a similar upside (+11.39%) but less analyst enthusiasm (2/3s recommended buying it), while Aroundtown had rather cautious analyst views — the price is currently above its expected value by 2% so expected to shrink, and the overriding advice is “Hold.”</p><p>Of the other differentiators that I’m interested in, there was one standout for dividend yield: Aedas and it’s staggering 16.97% — they paid an annual dividend of €2.58 per share last year, and with a price of €21.18, you could get 5 of these for just over €100 netting a cool €12.90 minus tax. Will they pay this much next year? I don’t know, but it’s definitely worth a look. Aroundtown doesn’t pay a dividend which was a big minus against them, especially considering the other 2 paid 3%-ish (Merlin 3.96%, Westfield 3.12%).</p><p>Each of these had their merits then, and though I am less inclined towards Aroundtown, I added all 4 to my Euro diversification matrix. I already own one European real estate stock but it was a wildcard, so I’m quite keen to get a stable stock in the one remaining Real Estate slot.</p><p>Looking at the country diversification, to be honest, I think there are much more attractive German stocks for the 6 remaining German places, so it looks very unlikely that I will take Aroundtown, and the fact that there were 2 strong candidates for the 2 Spanish spots means I will probably lean towards one of Merlin or Aedas. We’ll see what happens, and I’ll let you know which one of these I end up taking.</p><p><strong>What I bought</strong></p><p>Nothing this week, and probably nothing next week, but I am updating my prioritisation logic and shortlist with this influx of new European stocks.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=db0960a0b314" width="1" height="1" alt=""><hr><p><a href="https://medium.com/dave-invest-wards/portfolio-news-tuesday-30th-september-db0960a0b314">Portfolio News: Tuesday 30th September</a> was originally published in <a href="https://medium.com/dave-invest-wards">Dave Invest-wards</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Portfolio News: Monday 22 September]]></title>
            <link>https://medium.com/dave-invest-wards/portfolio-news-monday-22-september-6ce97153de91?source=rss----cdf37c015905---4</link>
            <guid isPermaLink="false">https://medium.com/p/6ce97153de91</guid>
            <category><![CDATA[value-investing]]></category>
            <category><![CDATA[stock-market]]></category>
            <category><![CDATA[investing]]></category>
            <dc:creator><![CDATA[David Edwards]]></dc:creator>
            <pubDate>Tue, 23 Sep 2025 16:23:41 GMT</pubDate>
            <atom:updated>2025-09-23T16:23:21.002Z</atom:updated>
            <content:encoded><![CDATA[<h3><strong>What’s new</strong></h3><p>This week I want to talk about <em>Intel</em>. For the longest time, this stock has been the absolute stinker in my portfolio. I bought my first block in October 2023 at $34.66 and by the end of 2023 it was over $50 — happy days. It immediately fell back, but I took a second block in July 2024 at $30.74…at which point it more or less immediately crashed and lost another $10 per share. Rather than panic, I doubled my position, and it became the only 4-unit stock in my portfolio.</p><p>I took Intel because in the semiconductor industry it seemed the most stable option. As Nvidia climbed higher and higher, I was discouraged by its price level — currently its P/E is at 50 (my usual threshold is 30) and its “Price to Book” value is an insane 42.85 (I usually hesitate at 2…). Intel seemed to tick all the boxes — it was an established company with sufficiently large sales, relatively low debt, paid a dividend, and it seemed appropriately priced (its Price to Book is currently 1.24, which is much more within my tolerance).</p><p>After the disastrous August 2024 earnings report, it probably wouldn’t have been a stock I would have picked, but I was already in so I decided I should take an additional stake while the price was low. It worked to an extent, bringing my average buy price down to $25.88. If I hadn’t done that, I would still be in the red, but I’d have missed my opportunity to buy this stock at a discount.</p><p>Fast forward 12 months, and this week the stock rallied… big time. We already had some good news, as the US government announced a partnership, Softbank acquired a $2 billion stake in August, and then this week a partnership agreement was announced with Nvidia and it absolutely launched on Thursday. Although it fell back a bit, it finished the week up 21.58% and month on month it’s up 28.5%. It finished the week at $29.58, up 14.3% on my new average buy price of $25.88.</p><p>What did I learn? I think this was a good example of why I use the Benjamin Graham framework and lean towards established giants and steady, defensive growth over high growth stocks. Intel certainly wasn’t too big to fail, and it has a long restructuring and journey back to profitability ahead, but its profile meant that I wasn’t the only one who found it attractive. I don’t know that if something similar happened to a smaller or less well-known industry player, these 3 bits of good news would necessarily have occurred and I would still be counting my losses rather than celebrating the fact that my big stinker has climbed back into the green.</p><h3>What I’ve been looking at</h3><p>Lightyear officially launched Austrian and Danish stocks, so I’m continuing to update my Euro stock watchlist. I noticed that a lot of additional Euro stocks have been added, so I’ve been doing a comprehensive analysis and working through the whole list, recalibrating my diversification matrix in the process.</p><p>This week I finished analysing 2 sectors. The first was the relatively small “Digital Hardware” sector and surprisingly there were not a lot of positive outcomes. Indeed, a solid half of the segment failed to return a Price per Earnings value, meaning they were not turning a profit, and of the remaining companies, only 7 fell under my target value of 30. However, whilst there were no 5-star stocks, I did find my first ever 6-star stock: take a bow <em>Jenoptik</em>. All 6 of the metrics I tested produced values within my tolerance and it even pays a modest dividend, and as it’s the only one above 5 in the segment, it goes into my watchlist.</p><p>“Communication” was the other segment I finished analysing. There were 40 stocks in here and though there weren’t any 6-stars, there were 7 5-stars in addition to Nokia, which I had already analysed earlier. The 7 5-star stocks were:</p><p><em>Ipsos (France)</em></p><p><em>Metropole Television (France)</em></p><p><em>1&amp;1 (Germany)</em></p><p><em>TF1 (France)</em></p><p><em>Telekom Austria (Austria)</em></p><p><em>Proximus PLC (Belgium)</em></p><p><em>Atresmedia (Spain)</em></p><p>All had sufficient revenue, none had experienced negative “eps” in the last 5 years, and all had PE ratios under 30, which was a good start. Atresmedia and Metropole Television offered over 9% dividend yields, and Proximus was my first Belgian stock, so these were particularly interesting.</p><p>Atresmedia was slightly overpriced against its book value, Proximus and Telekon Austria had debt ratios that were slightly outside of my tolerance, and the rest had shown negative 3-year EPS growth, meaning that while they weren’t making a loss, their earnings per share had shrunk across the last 3 years.</p><p>I added them all to my watchlist, let’s see how it goes. My next sector for analysis will be “Real Estate.”</p><h3>What I bought</h3><p>This week, my dollar fund was looking flush with dividend cash, so I took a look in the US market and bought a further unit of VICI. It’s a relatively stable up-and-down stock, bouncing between $27 and $34, but it’s a reliable dividend stock that just raised its dividend to $0.45 per share. According to my prioritisation logic, there aren’t any more stocks in my US watchlist with amazing growth potential or discounted prices, so VICI’s favourable dividend put it at the top of my list. Usually I would have waited and bought in the middle of the quarter, and the price of share immediately dropped once the ex-dividend passed, but I was keen to improve my position to take advantage of the October dividend payout so I paid the premium.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6ce97153de91" width="1" height="1" alt=""><hr><p><a href="https://medium.com/dave-invest-wards/portfolio-news-monday-22-september-6ce97153de91">Portfolio News: Monday 22 September</a> was originally published in <a href="https://medium.com/dave-invest-wards">Dave Invest-wards</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>